Premier Asset Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 6.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,349 shares of the company’s stock after purchasing an additional 249 shares during the quarter. Premier Asset Management LLC’s holdings in Johnson & Johnson were worth $563,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Zions Bancorporation N.A. raised its holdings in Johnson & Johnson by 0.4% during the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after buying an additional 73 shares during the period. Portland Global Advisors LLC raised its holdings in Johnson & Johnson by 0.9% during the 3rd quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after buying an additional 78 shares during the period. Vishria Bird Financial Group LLC raised its holdings in Johnson & Johnson by 3.0% during the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after buying an additional 80 shares during the period. Alta Capital Management LLC raised its holdings in Johnson & Johnson by 3.9% during the 3rd quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock worth $282,000 after buying an additional 82 shares during the period. Finally, G&S Capital LLC raised its holdings in Johnson & Johnson by 1.8% during the 3rd quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock worth $604,000 after buying an additional 84 shares during the period. 72.25% of the stock is currently owned by institutional investors.
Several analysts have commented on JNJ shares. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Raymond James dropped their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price on the stock in a report on Thursday, October 17th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Friday, October 11th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $151.64.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business earned $2.05 EPS. On average, analysts anticipate that Johnson & Johnson will post 8.65 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is Depreciation?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.